ABP-7 – 10MG

ABP-7 (Actin Binding Peptide-7, Ac-LKKTETQ) is a synthetic seven-amino-acid peptide corresponding to residues 17–23 of Thymosin Beta 4, the protein's central actin-binding domain. It is also known as the TB-500 Fragment. Published laboratory research on ABP-7, using cell, tissue and animal models, has examined wound repair, fibrosis and angiogenesis.

ABP-7 is a synthetic peptide, produced via solid-phase peptide synthesis.(1) Thymosin Beta 4 is posited to function as an actin-binding protein, particularly through its domain ABP-7.(2) This domain notably inhibits the polymerization of globular actin (G-actin) into filamentous actin (F-actin), a process termed actin sequestration. This inhibition may result in elevated levels of G-actin within the cell.

How Does ABP-7 Interact With Actin?

Actin, a pivotal component of the cellular cytoskeleton, is considered to not only provide structural integrity but may also play an essential role in various cellular activities, including cell motility and shape alteration. The mechanism by which ABP-7 may potentially prevent the polymerization of G-actin into F-actin appears to involve the stabilization of actin in its monomeric form, thereby limiting its availability to form the polymeric filaments necessary for a functional cytoskeleton. This alteration in the cytoskeletal architecture may impact the cell's ability to migrate and adapt its shape, which are considered to be critical functions in numerous biological processes.

For instance, studies in wound healing and tissue regeneration suggest that cell motility may enable cells to move into and populate damaged areas to facilitate repair and restoration. Moreover, the possible disruption of actin polymerization by ABP-7 may influence other cellular mechanisms tied to actin dynamics, including intracellular transport and signal transduction pathways that rely on the actin cytoskeleton.

ABP-7 Specifications

ABP-7 vs TB-500: What Is the Difference?

Thymosin Beta 4 is a 43-amino-acid protein; ABP-7 is only its 17–23 sequence, acetylated at the N-terminus. ABP-7 isolates the actin-binding region, while full-length Thymosin Beta 4 contains additional active sites studied separately.(2) The name "TB-500 Fragment" comes from the identification of this acetylated fragment in products sold as TB-500.(1) Full-length Thymosin Beta 4 is available as TB-500.

What Does Research Show About ABP-7?

Does ABP-7 Support Wound Repair in Research Models?

Key finding: In a 2003 mouse study, the synthetic LKKTETQ peptide promoted dermal wound repair in aged animals comparable to full-length Thymosin Beta 4.(3)

One study aimed to evaluate the actions of ABP-7, considered the central actin-binding domain of Thymosin Beta 4 (Tb4), focusing on its role in promoting wound repair in aged murine models. The peptide's potential to enhance wound healing was assessed by examining parameters such as keratinocyte migration, collagen deposition, and wound closure.(3)More specifically, the researchers posited that “the actin-binding domain of thymosin beta 4 duplicated in a seven-amino acid synthetic peptide, LKKTETQ, was able to promote repair in the aged animals comparable to that observed with the parent molecule.”

It is posited that the ABP-7 peptide may encourage epidermal cell migration and increase collagen deposition within the wound site. These activities suggest that the peptide might facilitate the closure and healing of wound models. The ABP-7 peptide, by mimicking a specific functional domain of Tb4, possibly harnesses similar biological pathways to promote wound repair, although the study suggests that further research is needed to fully understand the peptide's mechanism of action and its potential applicability in this specific field of study.

Studies have purported various mechanisms via which ABP-7 may speed up the healing of lesions and skin wounds.(4) One proposed mechanism suggests that ABP-7 may interact with purinergic receptors, which are considered to play pivotal roles in cellular responses to injury. The enhancement of wound healing observed in the presence of ABP-7 may be mediated by these receptors. The interaction may increase intracellular calcium levels, which is believed to be a critical factor in activating cellular pathways that facilitate wound closure. This rise in calcium levels might stimulate processes such as cell migration and extracellular matrix remodeling, which are essential for wound model repair.

Furthermore, the possibility that ABP-7 enhances the activation of downstream signaling pathways, such as those mediated by MAP kinases, cannot be ruled out. These pathways are considered to often regulate gene expression related to cell proliferation and migration. The modulation of these pathways by ABP-7 might enhance the cellular responses necessary for wound healing.

What Does Research Show About ABP-7 and Fibrosis?

Key finding: In hepatic stellate cell cultures, the actin-binding domain of Thymosin Beta 4 inhibited PDGF-BB-induced activation, proliferation and migration.(5)

Research has been undertaken to investigate the potential anti-fibrotic properties of ABP-7 and its actions on hepatic stellate cells (HSC) within the context of liver fibrosis. Preliminary data tentatively suggests that ABP-7 might potentially inhibit the PDGF-BB-dependent up-regulation of critical biomarkers such as PDGFβ receptor, α-smooth muscle actin (α-SMA), and collagen type I. Furthermore, it appears that ABP-7 may obstruct the phosphorylation of Akt at both T308 and S473 sites, which might consequently impede the phosphorylation of PRAS40. In elaborating on these pathways, the PDGF-BB-dependent up-regulation is believed to involve an enhancement of specific cellular signals initiated by PDGF-BB, a platelet-derived growth factor that engages and activates the PDGFβ receptor. The scientists commented that the fragment may have “prevented the PDGF-BB induced reappearance of the receptor protein once it is already degraded.”(5)

This receptor is considered crucial for cellular growth and division. α-Smooth muscle actin (α-SMA), serves as a marker for the transition of quiescent stellate cells into their contractile phenotype, considered a critical event in the development of fibrosis. Collagen type I is a principal component of the extracellular matrix that tends to accumulate during liver fibrosis. Regarding the signaling aspect, the phosphorylation of Akt at the T308 and S473 sites is hypothesized to activate Akt, potentially leading to the activation of several downstream proteins, including PRAS40, lauded as an essential regulator of cell survival and metabolism. The inhibition of these phosphorylation events may, theoretically, disrupt these signaling pathways, which are believed to be vital for the integral processes of cell proliferation and migration in fibrogenesis. This inhibition sequence is conjectured to correlate with a reduction in the proliferation and migration of activated HSCs.(5)

Does ABP-7 Affect Angiogenesis in Laboratory Studies?

Key finding: In laboratory assays, ABP-7 appeared to support endothelial cell migration, tube formation and vessel sprouting from aortic rings, the first steps of angiogenesis (the development of new blood vessels).(2)

These processes are considered essential for angiogenesis, where endothelial cells may migrate, align, and form tubular structures to establish new blood vessels. The addition of ABP-7 to these systems might indicate reduced interaction of actin with other cellular components by its actin-binding activity, thus potentially freeing up actin to participate more actively in the dynamic structural changes that endothelial cells undergo during angiogenesis. It is posited that by modifying actin's availability or organization within endothelial cells, ABP-7 might be influencing the cellular architecture in a way that favors angiogenic processes. This may involve cell shape and motility alterations, which are critical for forming new vascular structures. Given the complexity of angiogenic signaling and the multiple steps involved, it is also possible that ABP-7 may interact indirectly with other cellular pathways or signaling molecules that contribute to angiogenesis.

ABP-7 peptide is available for research and laboratory purposes only. We offer free shipping in the US for orders over $200. Please review our Terms and Conditionsbefore ordering.

References:

1. Esposito, S., Deventer, K., Goeman, J., Van der Eycken, J., & Van Eenoo, P. (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug testing and analysis, 4(9), 733–738. https://doi.org/10.1002/dta.1402

2. Sosne, G., Qiu, P., Goldstein, A. L., & Wheater, M. (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 24(7), 2144–2151. https://doi.org/10.1096/fj.09-142307

3. Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A. L., & Kleinman, H. K. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 11(1), 19–24. https://doi.org/10.1046/j.1524-475x.2003.11105.x